Skip to main content
Log in

Bevacizumab

Hypersensitivity: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Mahfoud T, Tanz R, Mesmoudi M, Khmamouche MR, Bazine A, Aassab R, Ismaili N, Boutayeb S, Ichou M, Errihani H.Bevacizumab 5 or 7.5 mg/kg in metastatic colorectal cancer can be infused safely over 10 minutes. Journal of Gastrointestinal Cancer 43: 244-248, No. 2, Jun 2012. Available from: URL: http://dx.doi.org/10.1007/s12029-010-9245-x - Morocco

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bevacizumab. React. Wkly. 1420, 14 (2012). https://doi.org/10.2165/00128415-201214200-00050

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214200-00050

Keywords

Navigation